Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. reported an 85% year-on-year revenue growth for 2024, driven by the acquisition of Yourgene, which contributed significantly to the clinical and instrumentation segments. The company achieved a gross profit margin of 163%, largely due to a one-time reversal of a product warranty provision. Despite a loss after tax of £41.8m, Novacyt has implemented strategic cost-saving measures, including site consolidations and the successful integration of Yourgene, which are expected to improve EBITDA by £3.0m annually. The company is focusing on launching new products in 2025 and investing in R&D to support growth in key areas, with confidence in achieving EBITDA profitability.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to deliver end-to-end solutions across sectors such as human health, animal health, and environmental. It operates through three business segments: Clinical, Instrumentation, and Research Use Only, with a presence in over 65 countries.
YTD Price Performance: -15.00%
Average Trading Volume: 150
Technical Sentiment Signal: Buy
Current Market Cap: $36.93M
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.